Compare · BSX vs ITMR
BSX vs ITMR
Side-by-side comparison of Boston Scientific Corporation (BSX) and Itamar Medical Ltd. (ITMR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and ITMR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.39B, about 143.9x ITMR ($503.1M).
- BSX has hit the wire 12 times in the past 4 weeks while ITMR has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 4 for ITMR).
- Company
- Boston Scientific Corporation
- Itamar Medical Ltd.
- Price
- $48.71+0.31%
- $30.87+0.85%
- Market cap
- $72.39B
- $503.1M
- 1M return
- -13.91%
- -
- 1Y return
- -51.31%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- n/a
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 4
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Itamar Medical Ltd.
Itamar Medical Ltd., a medical technology company, develops and commercializes non-invasive medical devices and solutions for the treatment of respiratory sleep disorders. The company offers medical devices based on Peripheral Arterial Tone (PAT) signal, which measures changes in the patient's peripheral arterial pulse volumes and various parameters of arterial activities. It provides WatchPAT device, which enable to conduct home sleep apnea tests for the treatment of sleep apnea, such as obstructive sleep apnea; EndoPAT device that diagnoses endothelial dysfunction; and Loop device, a wrist device for measuring and recording physiological parameters, such as SpO2, respiration rate, and heart rate. The company operates in the United States, Canada, Europe, Israel, Japan, rest of the Asia Pacific, and internationally. The company was formerly known as Itamar Medical (CM) 1997 Ltd. and changed its name to Itamar Medical Ltd. in July 2000. Itamar Medical Ltd. was incorporated in 1997 and is headquartered in Caesarea, Israel.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest ITMR
- SEC Form 15-12B filed by Itamar Medical Ltd.
- SEC Form EFFECT filed by Itamar Medical Ltd.
- SEC Form EFFECT filed by Itamar Medical Ltd.
- SEC Form POS AM filed by Itamar Medical Ltd.
- SEC Form POS AM filed by Itamar Medical Ltd.
- SEC Form S-8 POS filed by Itamar Medical Ltd.
- SEC Form S-8 POS filed by Itamar Medical Ltd.
- SEC Form 25-NSE filed by Itamar Medical Ltd.
- SEC Form 6-K filed by Itamar Medical Ltd.
- SEC Form 6-K filed by Itamar Medical Ltd.